Argenica Therapeutics Limited announce the completion of the preliminary pre-clinical toxicology studies in both rat and non-human primates (NHPs), and preliminary in vitro genotoxicity studies. These studies, carried out under non-Good Laboratory Practice (non-GLP) conditions, are necessary to identify the suitable dose ranges for further testing under the principles of Good Laboratory Practice (GLP) and provide an indication of the no observed adverse effect level (NOAEL) of ARG-007 required for determining the doses for the Phase 1 clinical trial. Given Argenica has completed the non-GLP studies necessary for the progression of the required GLP studies, the Company has now begun the final GLP studies for pharmacokinetics (PK) and toxicity, and safety studies will follow shortly after.

These GLP studies will confirm the safety and tolerability of single doses of ARG-007 prior to commencement of the Phase 1 clinical trial. The results of these pre-clinical studies will be reported throughout First Quarter CY22. The GLP genotoxicity studies are nearing completion and the results will be reported within First Quarter 2022.